Basic Information
IXIARO Suspension for Injection 0.5ml in pre-filled syringe
INJECTION, SUSPENSION
Regulatory Information
SIN14108P
February 16, 2012
Prescription Only
Therapeutic
INTRAMUSCULAR
August 10, 2023
June 4, 2025
XJ07BA02
Company Information
AENON PHARMACEUTICALS SEA PTE. LTD.
AENON PHARMACEUTICALS SEA PTE. LTD.
Active Ingredients
Strength: 6 μg/0.5 mL
Detailed Information
Contraindications
**4.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_ or to the residues protamine sulphate, formaldehyde, bovine serum albumin, host cell DNA, sodium metabisulphite, host cell protein. Individuals who show hypersensitivity reactions after receiving the first dose of the vaccine should not be given the second dose. Administration must be postponed in persons with acute severe febrile conditions.
Indication Information
**4.1 Therapeutic indications** IXIARO is indicated for active immunization against Japanese encephalitis in adults, adolescents, children and infants aged 2 months and older. IXIARO should be considered for use in individuals at risk of exposure through travel or in the course of their occupation.